Suggested remit: To appraise the clinical and cost effectiveness of topical tapinarof within its marketing authorisation for treating mild to severe plaque psoriasis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- Criteria within the VPAG met as a new active substance.
- Process:
- STA Standard
- ID number:
- 6712
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6712:
- 02 June 2026 - 30 June 2026
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 June 2026 | In progress. Scoping commencing |
| 22 January 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 22 January 2026 | Topic prioritisation |
For further information on our processes and methods, please see our CHTE processes and methods manual